JSPR · Jasper Therapeutics, Inc.
Jasper Therapeutics Inc (JSPR)
What's happening
- JSPR is up 1.54% today, trading at $0.51. — Live quote
- Volume today (583) is well below its 3-month average of 1,109,570. (Finnhub fundamentals)
- Reports earnings on 2026-11-09 (before market open), 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.10 actual vs. $-0.36 estimated (+72.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $11.6M | $25.5M | $39.6M | $85.4M | $64.8M |
| P/E | -0.23 | -0.38 | -0.46 | -1.05 | -0.95 |
| Price/Book | 8.19 | 7.51 | 3.42 | 3.63 | 1.53 |
| ROE | -3495.61% | -1996.29% | -737.51% | -345.45% | -161.42% |
| ROA | -418.51% | -320.40% | -148.49% | -174.72% | -118.39% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -80.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on JSPR
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$9.2M | -$11.0M | -$19.2M | -$27.1M | -$21.8M | -$19.9M | -$16.0M | -$15.1M |
| Net income | -$2.8M | -$1.2M | -$18.7M | -$26.7M | -$21.2M | -$18.6M | -$14.6M | -$13.7M |
| EPS (diluted) | $-0.10 | $-0.04 | $-1.13 | $-1.74 | $-1.41 | $-1.24 | $-0.97 | $-1.03 |
| EPS (basic) | $-0.10 | $-0.04 | $-1.13 | $-1.74 | $-1.41 | $-1.24 | $-0.97 | $-1.03 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $11.8M | $21.2M | $35.8M | $57.5M | $46.5M | $57.6M | $79.9M | $99.4M |
| Total liabilities | $10.4M | $17.8M | $31.6M | $45.9M | $23.0M | $15.4M | $18.2M | $15.7M |
| Stockholders' equity | $1.4M | $3.4M | $4.2M | $11.6M | $23.5M | $42.2M | $61.7M | $83.7M |
| Total current assets | $11.6M | $20.3M | $34.6M | $54.6M | $43.0M | $53.2M | $75.8M | $94.8M |
| Total current liabilities | $7.8M | $9.0M | $13.2M | $21.0M | $20.5M | $12.3M | $15.2M | $12.5M |
| Cash & equivalents | $7.3M | $14.1M | $28.7M | $50.9M | $39.5M | $48.8M | $71.6M | $92.5M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Other current assets | $255.0K | $405.0K | $664.0K | $863.0K | $867.0K | $854.0K | $646.0K | $625.0K |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $60.0K | $81.0K | $102.0K | $1.1M | $1.3M | $1.6M | $1.9M | $2.1M |
| Other non-current assets | $43.0K | $77.0K | $113.0K | $150.0K | $192.0K | $532.0K | $820.0K | $1.0M |
| Accounts payable | $2.8M | $2.4M | $6.2M | $9.2M | $8.0M | $3.0M | $4.0M | $3.1M |
| Accrued liabilities | — | — | — | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M | $2.3M |
| Common stock & paid-in capital | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K |
| Retained earnings | -$320.6M | -$317.8M | -$316.7M | -$307.6M | -$288.8M | -$262.1M | -$240.9M | -$216.5M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.9M | -$14.5M | -$21.9M | -$17.0M | -$15.5M | -$22.8M | -$21.1M | -$14.1M |
| Investing cash flow | $80.0K | — | $0 | $0 | $1.0K | $4.0K | -$76.0K | -$274.0K |
| Financing cash flow | $9.0K | — | -$340.0K | $28.4M | $6.2M | — | $345.0K | $9.0K |
| Free cash flow | — | — | — | — | -$15.5M | — | — | — |
| Capital expenditures | — | — | — | — | $7.0K | — | — | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $764.0K | $423.0K | $1.7M | $1.4M | $1.8M | $1.8M | $2.0M | $2.0M |
| Change in accounts payable | $339.0K | -$3.8M | -$2.9M | $1.1M | $5.0M | -$1.0M | $957.0K | $222.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | -$36.8M |
| Net income | -$75.8M | -$71.3M | -$64.5M | -$37.7M | -$30.6M |
| EPS (diluted) | $-3.95 | $-4.89 | $-6.18 | $-10.33 | $-2.69 |
| EPS (basic) | $-3.95 | $-4.89 | $-6.18 | $-10.33 | $-2.69 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M |
| Stockholders' equity | $4.2M | $61.7M | $78.4M | $36.0M | $69.5M |
| Total current assets | $34.6M | $75.8M | $88.9M | $41.7M | $87.8M |
| Total current liabilities | $13.2M | $15.2M | $12.4M | $7.1M | $8.0M |
| Cash & equivalents | $28.7M | $71.6M | $86.9M | $38.2M | $84.7M |
| Other current assets | $664.0K | $646.0K | $295.0K | $118.0K | $219.0K |
| Marketable securities (non-current) | — | — | — | — | — |
| Property, plant & equipment | $102.0K | $1.9M | $2.7M | $3.6M | $3.7M |
| Other non-current assets | $113.0K | $820.0K | $1.3M | $759.0K | $645.0K |
| Accounts payable | $6.2M | $4.0M | $4.1M | $1.8M | $3.9M |
| Other current liabilities | — | — | — | $194.0K | $585.0K |
| Other non-current liabilities | $2.3M | $2.3M | $2.3M | $2.4M | $643.0K |
| Common stock & paid-in capital | $3.0K | $2.0K | $1.0K | $4.0K | $4.0K |
| Retained earnings | -$316.7M | -$240.9M | -$169.6M | -$105.1M | -$67.5M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M |
| Investing cash flow | $5.0K | -$532.0K | -$267.0K | -$576.0K | -$2.4M |
| Financing cash flow | $34.2M | $47.9M | $101.0M | $55.0K | $101.0M |
| Depreciation & amortization | — | — | $1.1M | $975.0K | — |
| Share-based compensation | $6.7M | $6.6M | $5.2M | $4.1M | $1.0M |
| Change in accounts payable | $2.2M | -$122.0K | $2.4M | -$2.2M | $2.9M |
| Tax withholding on stock comp | — | — | $960.0K | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding JSPR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-09-22 to 2025-09-22
Recent transactions
- Most recent: WIGGANS THOMAS G (Director) — Open market purchase of 41,000 shares on 2025-09-22.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| WIGGANS THOMAS G | Director | Open market purchase | 2025-09-22 | 41,000 |
| Lucas Svetlana | Director | Open market purchase | 2025-09-22 | 20,000 |
| MARTELL RON | President and CEO | Open market purchase | 2025-09-22 | 41,000 |
| Shizuru Judith Anne | Director | Open market purchase | 2025-09-22 | 41,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-09-22 | WIGGANS THOMAS G | Director | Open market purchase | 41,000 | $2.43 |
| 2025-09-22 | Lucas Svetlana | Director | Open market purchase | 20,000 | $2.43 |
| 2025-09-22 | MARTELL RON | President and CEO | Open market purchase | 41,000 | $2.43 |
| 2025-09-22 | Shizuru Judith Anne | Director | Open market purchase | 41,000 | $2.43 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:37 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-07 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-10-05 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-09-28 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-08-26 | 8-K | 2026-08-21 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-07-31 | View on SEC.gov → |
Recent news
Headlines about JSPR (Jasper Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
JSPR DEF 14A & SEC Filings
Yahoo Finance · 2026-10-19 -
JSPR 8-K & SEC Filings
Yahoo Finance · 2026-10-16 -
Jasper completes 18-patient study. Jasper Therapeutics stock is valued at USD 17.7 million - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15 -
JSPR270416C00000500 Interactive Stock Chart | JSPR Apr 2027 0.500 call Stock
Yahoo Finance · 2026-10-15 -
Jasper (JSPR) Up +1.40% — Should You Chase the Rally? 2026-10-15 - Factor Timing
https://www.dars.gov.et/ · 2026-10-15 -
Kidney study cohort enrollment ends at Jasper Therapeutics (JSPR), with interim data expected by year-end 2026.
Stock Titan · 2026-10-15 -
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
Yahoo · 2026-10-15 -
William Blair Reinstates Outperform on Jasper Therapeutics
Benzinga · 2026-10-14
No headlines in this category right now — try “All”.